Target, Home Depot,...
Health Care: Drugs
DARA Biosciences Inc. (DARA: NASDAQ)
$0.70 -0.04 | -5.06%
05/17/13 - 03:59 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 6.50M | 1.18M | 5.48M | 3.17M |
| Receivables | 173.38K | 0.00 | 0.00 | 0.00 |
| Inventories | 125.28K | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 7.04M | 1.46M | 5.83M | 3.32M |
| Property, Plant & Equipment, Gross | 203.49K | 187.82K | 190.57K | 158.52K |
| Accumulated Depreciation & Depletion | 153.30K | 145.37K | 127.22K | 102.31K |
| Property, Plant & Equipment, Net | 50.19K | 42.46K | 63.36K | 56.21K |
| Intangibles | 3.71M | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 67.31K | 347.02K | 549.20K | 765.89K |
| Total Non-Current Assets | 4.65M | 389.48K | 612.56K | 822.10K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 11.69M | 1.85M | 6.44M | 4.14M |
| Accounts Payable | 1.38M | 640.82K | 349.74K | 374.56K |
| Short Term Debt | 7.17K | 15.31K | 13.22K | 6.34K |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 2.04M | 868.00K | 914.80K | 665.47K |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 40.86K | 9.10K | 12.05K | 10.97K |
| Other Non-Current Liabilities | 599.45K | 0.00 | 287.62K | 286.52K |
| Minority Interest | -429.34K | -306.66K | -339.49K | -218.34K |
| Total Non-Current Liabilities | 15.64K | -190.09K | 422.45K | 750.36K |
| Total Liabilities | 2.05M | 677.90K | 1.34M | 1.42M |
| Preferred Stock Equity | 19.00 | 8.00 | 37.00 | 0.00 |
| Common Stock Equity | 9.64M | 1.17M | 5.11M | 2.72M |
| Common Par | 189.47K | 56.01K | 41.26K | 446.34K |
| Additional Paid In Capital | 56.43M | 40.83M | 38.61M | 30.17M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -47.03M | -39.72M | -33.55M | -27.89M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 45.47K | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 9.64M | 1.17M | 5.11M | 2.72M |
| Total Equity | 9.64M | 1.17M | 5.11M | 2.72M |
| Total Liabilities & Stock Equity | 11.69M | 1.85M | 6.44M | 4.14M |
| Total Common Shares Outstanding | 18.95M | 5.60M | 4.13M | 2.79M |
| Preferred Shares | 1.94K | 828.00 | 3.68K | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 12.11M | 5.15M | 3.13M | 2.19M |
| Diluted Weighted Shares Outstanding | 12.11M | 5.15M | 3.13M | 2.19M |
| Number of Employees | 17 | 8 | 5 | 5 |
| Number of Part-Time Employees | 1 | 1 | 1 | 0 |
Portfolios with DARA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserStan/Gino
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserIf you can't join them,whup...
- Usergarym
Latest DARA Headlines from TheStreet
- 5 Stocks Under $10 Poised to Pop 01.24.13 | 12:01 pm
- 5 Stocks Under $10 Set to Soar Higher 09.27.12 | 01:09 pm
- 3 Stocks Under $5 Moving Higher 09.13.12 | 02:09 pm
- 5 Stocks Under $10 Set to Soar Higher 08.30.12 | 12:08 pm
- Report From Results Of A Successful Phase II Study For DARA's KRN5500 At ADEPT 03.29.11 | 08:03 am
- DARA BioSciences Filing Shelf Registration Statement To Replace Expiring Registration Statement 03.25.11 | 04:03 pm
- DARA BioSciences Is Selected By MDB Capital Group As A 2011 "Best & Brightest-Company To Watch" 02.23.11 | 08:02 am
- DARA BioSciences To Present At The Wall Street Analyst Forum 22nd Annual Analyst Conference 02.17.11 | 09:02 am
- Agile Companies Like DARA BioSciences Advance Research For New Diabetes Medicines As Incidence Of Disease Relentlessly Increases 02.15.11 | 09:02 am
- Study Results For DARA Biosciences' Lead Drug For Neuropathic Pain, KRN5500, Selected For Presentation By The International Conference On Accelerating The Development Of Enhanced Pain Treatments ("ADEPT") 02.01.11 | 08:02 am
Press Releases for DARA
- DARA BioSciences Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule - Business Wire 02.14.13 | 08:02 am
- DARA BioSciences To Present At 15th Annual BIO CEO & Investor Conference - Business Wire 02.11.13 | 08:02 am
- DARA BioSciences To Present At The 6th Annual OneMedForum Conference - Business Wire 01.08.13 | 08:01 am
- DARA BioSciences To Raise $2.8 Million Pursuant To Securities Purchase Agreement - Business Wire 12.31.12 | 08:12 am
- DARA BioSciences Announces Submission Of KRN5500 To FDA For Orphan Designation - Business Wire 11.29.12 | 08:11 am
- Dara Biosciences Reports Financial Results For The Third Quarter 2012 - Business Wire 11.14.12 | 05:11 pm
- DARA BioSciences Will Present At NYSSA Investing In Life Sciences Conference, November 29 - Business Wire 11.12.12 | 09:11 am
- DARA BioSciences Will Present At Singular Research Conference November 1 - Business Wire 10.29.12 | 03:10 pm
- Soltamox, Liquid Version Of Tamoxifen Citrate (Photo: Business Wire) - Business Wire 10.22.12 | 06:10 am
- Soltamox, Liquid Version Of Tamoxifen Citrate (Photo: Business Wire) - Business Wire 10.22.12 | 06:10 am
Partner Headlines for DARA
- Benzinga's Small Cap Movers for Friday November 16, 2012 - Benzinga 11.18.12 | 11:11 am
- Benzinga's Microcap Movers for Friday September 14, 2012 - Benzinga 09.15.12 | 08:09 pm
- DARA Biosciences Inks Deal - Analyst Blog - NASDAQ 08.23.12 | 10:08 pm
- DARA Biosciences Inks Deal - Analyst Blog - Zacks 08.23.12 | 07:08 pm
- DARA Bio Starting To Look Interesting - Analyst Blog - Zacks 05.08.12 | 10:05 am
- Morning Market Losers - Benzinga 04.09.12 | 09:04 am
- Morning Market Movers - Benzinga 03.26.12 | 09:03 am
- DARA BioSciences Spiking Higher after Positive Phase I Results - Benzinga 06.28.11 | 09:06 am
- Life Sciences Companies Raise Record Amounts of Capital - Seeking Alpha 12.31.10 | 04:12 pm
- News Summary - Benzinga 12.29.10 | 09:12 am
